This week's headlines saw a wave of high-stakes oncology investment as companies race to secure next-generation therapeutic platforms; persistent pressure on supply chain resilience and drug availability; and the growing importance of operational readiness—whether that means data infrastructure for AI, carbon accountability, or access systems for complex modalities like radiopharmaceuticals.
In news this week, GSK has agreed to acquire Nuvalent for $10.6 billion, gaining two late-stage kinase inhibitors targeting ROS1 and ALK alterations in non-small cell lung cancer—both carrying FDA Breakthrough Therapy designations with potential approval decisions later this year.
Johnson & Johnson and Roche have committed a combined $4 billion to protein degrader platforms—J&J acquiring Firefly Bio for its tumor-targeted degrader conjugate technology, and Roche licensing Nurix's BTK degrader bexobrutideg—signaling that targeted protein degradation is becoming a primary pipeline priority in oncology.
The European Medicines Agency published its 2025 annual report, which detailed the agency’s approval of 104 human medicines in 2025, including 38 new active substances and several first-in-class therapies, while also advancing a draft policy that could reduce the clinical data burden for biosimilar development.
The US Pharmacopeia’s 2025 annual drug shortages report found that while the total number of shortages declined by 23% in 2025, drug discontinuations rose 60% year-over-year—with low-priced generics and sterile injectables at highest risk, pointing to structural fragility in the supply base.
On PharmTech.com this week, Nicholas Richardson, vice president of clinical development at Precision for Medicine, explained how radiopharmaceuticals require an integrated system of isotope production, just-in-time distribution, nuclear medicine licensing, and trained personnel that makes patient access inherently complex—and developers must build site strategy and supply chain infrastructure into development planning from the outset.
Expert Molly Klote argues that companies must move beyond reactive tariff responses and build documented, quality-led supply chain resilience strategies — including dual sourcing and qualified backup suppliers — that can withstand FDA scrutiny and protect patient access.
Partha Anbil and Vineet Kumar explain how pharmaceutical organizations should evaluate three clinical data architectures — data warehouses, data lakes, and data lakehouses — based on their AI readiness, governance requirements, and technical capacity, with the lakehouse model offering the most comprehensive capabilities for large research-intensive institutions.
And finally, at CPHI Americas, David Vázquez, climate principal consultant, Nexius Projects, spoke about how pharmaceutical suppliers face growing pressure to calculate and report product-level carbon footprints as major customers like AstraZeneca, the UK NHS, and regulators in France begin mandating emissions data—with experts noting that carbon accounting also surfaces manufacturing inefficiencies that can reduce costs.
Thank you for watching. Be sure to read all the news and feature content on PharmTech.com.
